Nelarabine has been approved in the United States

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


nelarabine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
COG P9673 (PGAA2001) II A Phase II Study of 506U78 in Patients with Refractory T-Cell Malignancies – CCG Intergroup Study
PGAA2003 II A Multicenter Study to Assess the Efficacy of 506U78 in Subjects with Chronic Lymphocytic Leukemia (CLL) who are Refractory to Fludarabine and Alkylator Therapy
PGAA1001 I A phase I study of 2-amino-9-b-D-arabinofuranosyl-6-methoxy-9H-purine (Compound 506) in children and adults with refractory hematologic malignancies.
PGAA1002 I A phase I study of 506U78 administered as a two hour infusion daily for 3 consecutive days in adult patients and as a two hour infusion daily over 5 consecutive days in pediatric patients with refractory hematologic malignancies.
PGAA1003 I Phase I study of 506U78 administered as a two hour infusion on a day 1, 3, and 5 schedule in patients with refractory hematologic malignancies.
PGAA1005 I Pilot study of pharmacodynamic investigation of treatment with 506U78 combined with fludarabine in refractory leukemics.